Aligos Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Aligos Therapeutics generated cash of -$78,997,000, which is more than the previous year. Cash used in financing activities reached the amount of $88,328,000 last year. Net change in cash is therefore $54,312,000.
Cash Flow
| 2018 | -6.04M | -69.28M | 99.88M |
|---|---|---|---|
| 2019 | -46.76M | 6.79M | 85.53M |
| 2020 | -74.26M | 32.75M | 192.34M |
| 2021 | -115.66M | 3.02M | 78.67M |
| 2022 | -79.38M | -26.29M | 164K |
| 2023 | -78.99M | 44.98M | 88.32M |
ALGS Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 81.46M | 186.98M | 220.94M | 70.10M | 24.54M | 0 |
Operating activities | ||||||
Net income | -87.67M | -96.04M | -128.33M | -108.54M | -52.26M | -13.93M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 3.06M | 3.67M | 3.77M | 3.32M | 2.29M | 1.29M |
Stock-based compensation expense | 12.65M | 14.69M | 13.45M | 2.97M | 752K | 0 |
| Deferred income tax benefit | 12.65M | 14.69M | 13.45M | 2.97M | 752K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -2.21M | 1.72M | -313K | -130K | 385K | 2.97M |
Cash generated by operating activities | -78.99M | -79.38M | -115.66M | -74.26M | -46.76M | -6.04M |
Investing activities | ||||||
Purchases Of Investments | -11K | -104.26M | -19.08M | -45.28M | -70.42M | -66.77M |
Investments In Property Plant And Equipment | -19K | -943K | -892K | -2.06M | -2.78M | -2.51M |
Acquisitions Net | 0 | 25.35M | -3.91M | -34.81M | -9.57M | 0 |
Cash generated by investing activities | 44.98M | -26.29M | 3.02M | 32.75M | 6.79M | -69.28M |
Financing activities | ||||||
Common Stock Issued | 17.44M | 20K | 78.58M | 155.54M | 85.57M | 2K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -96K | -61K | -79K | -58K | -43K | -1K |
Cash used in financing activities | 88.32M | 164K | 78.67M | 192.34M | 85.53M | 99.88M |
Net Change In Cash | 54.31M | -105.51M | -33.96M | 150.84M | 45.55M | 24.54M |
Cash at end of period | 135.77M | 81.46M | 186.98M | 220.94M | 70.10M | 24.54M |
| Data source | Data source | Data source | Data source |